Annovis Bio - Buntanetap - the share price is down and I wonder why?
There are conflicting reports about trial participants in phase 3 and also financially Annovis Bio is a bit weak, but such a bad share price?
Maybe this means that "Buntanetap" will not make it through the phase 3 trial successfully after all. Often the "insiders" know more. And with such a small company...
What do you think?
I still have very high hopes for a successful phase 3, as it would be a very interesting drug without major side effects.
From my point of view the most interesting at the moment!